Search research articles
Contact Us
Filters
Showing results (1571-1580 of 1,873) with videos related to
Page
of 188
Sort By:
Circulation. Heart Failure
|
November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Jawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Lancet (London, England)
|
December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R Teerlink, G Michael Felker, John J V McMurray, et al.
Circulation
|
October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
John W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure
|
February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure
|
December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Xiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure
|
August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF
Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
American Heart Journal
|
May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER
Ankeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
European Journal of Heart Failure
|
May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF
Safia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure
|
August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
Sara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
European Heart Journal
|
August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation
Toru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
Page
of 188
Search research articles
Search
Showing results (1571-1580 of 1,873) with videos related to
Sort By:
Page
of 188
Circulation. Heart Failure
|
November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Jawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Lancet (London, England)
|
December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R Teerlink, G Michael Felker, John J V McMurray, et al.
Circulation
|
October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
John W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure
|
February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure
|
December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Xiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure
|
August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF
Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
American Heart Journal
|
May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER
Ankeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
European Journal of Heart Failure
|
May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF
Safia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure
|
August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
Sara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
European Heart Journal
|
August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation
Toru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
Page
of 188